Cara Therapeutics (TVRD): Pangali EV/EBITDA

Logo perusahaan publik Cara Pharma (TVRD)

Due to the failure of primary trials, Cara Therapeutics Inc (TVRD) has scaled back development and is now merely minimizing expenses to preserve liquidity. Stable demand for nephrology products supports the business, although geopolitical tensions are hindering international testing. The company's price chart with the 0.00 indicator complements the analysis, while the enterprise strictly adheres to environmental regulations regarding wastewater treatment and chemical disposal.

Cara Pharma - Nilai perusahaan marang bathi operasional sadurunge panyusutan TVRD (periode 23.11.2025 - 17.11.2026)

TVRD (Cara Pharma): rincian analitis lan laporan miturut indikator

- rega pasar lan target rega analis:
Analisis wiwitan perusahaan:caratherapeutics.com TVRD
Sampel barang Cara Therapeutics, Inc.

Investors find it difficult to reconcile the market value of Cara Therapeutics Inc (TVRD) with the actual risks of its debt load. The company's EV/EBITDA multiple combines market capitalization and net debt, weighing them against operating profit before taxes and amortization. This chart allows for a determination of the extent to which assets are overvalued. Amid fierce competition in the kidney therapy niche, such a valuation is critical for understanding the business's resilience against expansion by pharma behemoths.